Analytical Tool - Lung Cancer is a
premium combo product of "Lung Cancer: A Decision Support Tool for
Optimizing the Pipeline from Research To Market" and "Lung Cancer
Drug Pipeline Update 2013".
According to market analytical
studies, the therapeutic lung cancer drug market is predicted to exceed $4
billion between 2010 and 2015. Chemotherapy drugs will experience generic
erosion and three major chemotherapy drugs go off patent before 2012; Aventis
Taxotere (docetaxel), Bristol-Myers Squibbs Paraplatin (carboplatin) and Eli
Lillys Gemzar (gemcitabine). The third-generation chemotherapeutic agents have
expanded the therapeutic options in the treatment of advanced lung cancer.
However, despite their contributions, science has reached a therapeutic
plateau. Indeed, both Avastin and Efaproxyn have generated exciting data.
This combo product assists in your
strategic planning decisions in oncology drug development. Understand the
clinical and strategic challenges towards the commercialization of drugs in
lung cancer treatments. Assess opportunities and risks for the continued
development of innovative developmental treatments.
Find out more about each product by clicking on respective
links.
This software application is a
searchable database reflects the most recent advances in the field of lung
cancer drug development, in order to help you perform your own analysis, go
back to the source data for in-depth information, and present the research and
development in tables and graphs suited for your own specific purposes. A
significant advantage with BioSeeker's software applications is that they
provide you with well-structured information. Each pipeline drug/project has
been carefully defined and classified in categories and subcategories. The main
categories include therapy type, effect, mechanism of action (molecular
target), indication, stage of development etc. These categories are further
organized and classified in sub-categories. In comparison with other available
databases, BioSeekers software applications give better overview, specific
search capabilities and great dynamic reports.
